DR. CLAY F SEMENKOVICH, MD
Osteopathic Medicine at Parkview Pl, Saint Louis, MO
License number
Missouri R6C91
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
Address
Address
4921 Parkview Pl STE 13B, Saint Louis, MO 63110
Phone
(314) 362-3500
(314) 362-7641 (Fax)
(314) 362-7641 (Fax)
Personal information
See more information about CLAY F SEMENKOVICH at radaris.comName
Address
Phone
10 Rio Vista Dr, Saint Louis, MO 63124
Ladue, MO
10 Rio Vista Dr, Saint Louis, MO 63124
4570 Childrens Pl, Saint Louis, MO 63110
4921 Parkview Dr, Saint Louis, MO 63110
Organization information
See more information about CLAY F SEMENKOVICH at bizstanding.comLipid Center
4570 Childrens Pl, Saint Louis, MO 63110
Industry:
Medical Doctor's Office, Offices and Clinics of Medical Doctors, Nsk
Doing business as:
Lipid Center - Clay F Semenkovich MD<br>Lipid Center - Gustav Schonfeld MD
Registration:
Aug 18, 2010
Phone:
(314) 362-3500 (Phone)
Manager:
Manager (Manager)
Categories:
Physicians & Surgeons - Medical-M.D., Endocrinology & Metabolism Physicians & Surgeons, Clinics & Medical Centers, ...
Products:
Including Bone Marrow Transplantation, Hematology, Head & Neck Cancer, Gamma Knife, Gynecologic, Medical and Surgical Oncology, Radiation Oncology, Pediatric Services, Physicians, ...
Certifications:
Physicians
Additional:
Washington University in St. Louis, The Center for Advanced Medicine-Providing World Class Medical Expertise and Compassionate Care - Is the Region's Only Fully Integrated Outpatient Medical Center fo...
Professional information
See more information about CLAY F SEMENKOVICH at trustoria.com
Clay Farmer Semenkovich, Saint Louis MO
Clay Farmer Semenkovich, Saint Louis MO
Specialties:
Internal Medicine, Endocrinology and Metabolism, Endocrinology, Diabetes & Metabolism
Work:
Washington University at St. Louis
4921 Parkview Pl, Saint Louis, MO 63110 Washington University at St. Louis
660 S Euclid Ave, Saint Louis, MO 63110
4921 Parkview Pl, Saint Louis, MO 63110 Washington University at St. Louis
660 S Euclid Ave, Saint Louis, MO 63110
Education:
Washington University at St. Louis (1981)
Dr. Clay F Semenkovich, Saint Louis MO - MD (Doctor of Medicine)
Dr. Clay F Semenkovich, Saint Louis MO - MD (Doctor of Medicine)
Specialties:
Endocrinology, Diabetes & Metabolism, Endocrinology & Metabolism
Address:
Saint Louis Office
660 S Euclid Ave, Saint Louis 63110
(314) 362-5000 (Phone), (314) 454-5396 (Fax)
Barnes Jewish Hosp Dbts Ctr
4921 Parkview Pl SUITE 13B, Saint Louis 63110
(314) 747-7300 (Phone)
660 S Euclid Ave, Saint Louis 63110
(314) 362-5000 (Phone), (314) 454-5396 (Fax)
Barnes Jewish Hosp Dbts Ctr
4921 Parkview Pl SUITE 13B, Saint Louis 63110
(314) 747-7300 (Phone)
Certifications:
Diabetes, Metabolism & Endocrinology, 1987, Internal Medicine, 1984
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Washington Center / School of Medicine
Graduated: 1981
Barnes-Jewish Hospital
Washington University
Washington Center / School of Medicine
Graduated: 1981
Barnes-Jewish Hospital
Washington University
Use Of Chloroquine To Treat Metabolic Syndrome
Use Of Chloroquine To Treat Metabolic Syndrome
US Patent:
8440695, May 14, 2013
Filed:
Oct 31, 2006
Appl. No.:
12/093198
Inventors:
Michael B. Kastan - Cordova TN, US
Clay F. Semenkovich - Ladue MO, US
Jochen Schneider - St. Louis MO, US
Clay F. Semenkovich - Ladue MO, US
Jochen Schneider - St. Louis MO, US
Assignee:
St Jude Children's Research Hospital - Memphis TN
The Washington University - St. Louis MO
The Washington University - St. Louis MO
International Classification:
A61K 31/47
US Classification:
514313
Abstract:
The present invention provides methods and compositions for modulating certain metabolic processes and for treating a variety of disorders associated with metabolic syndrome, including insulin related disorders, ischemia, oxidative stress, atherosclerosis, hypertension, obesity, abnormal lipid metabolism, and stroke by administering an effective dose of a chloroquine compound. The invention also provides methods and compositions relating to administering an effective dose of a chloroquine compound in combination with at least a second pharmaceutically active ingredient or compound including an antihyperglycemic diabetes treatment, an antihypertensive agent, an antithrombotic agent, and/or an inhibitor of cholesterol synthesis or absorption.
Use Of An Endogenous Ligand For Peroxisome Proliferator Activated Receptor Alpha To Treat Liver Disorders
Use Of An Endogenous Ligand For Peroxisome Proliferator Activated Receptor Alpha To Treat Liver Disorders
US Patent:
2010026, Oct 14, 2010
Filed:
Apr 12, 2010
Appl. No.:
12/758523
Inventors:
Clay F. Semenkovich - Ladue MO, US
Manu V. Chakravarthy - Scotch Plains NJ, US
John W. Turk - Eureka MO, US
Manu V. Chakravarthy - Scotch Plains NJ, US
John W. Turk - Eureka MO, US
Assignee:
WASHINGTON UNIVERSITY - St. Louis MO
International Classification:
A61K 31/685, C07F 9/06, A61P 1/16, G01N 33/48
US Classification:
514 78, 554 80, 436 63
Abstract:
Compositions comprising the peroxisome proliferator-activated receptor alpha (PPARĪ±)-ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC) are disclosed. These compositions may be used for the prophylaxis and treatment of PPARĪ±-related liver disorders including, but not necessarily limited to, fatty liver disease, to lower lipid and triglyceride levels, and to increase high density lipoprotein levels in animals. Foods modified with 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1GPC) may be used to improve the metabolism of animals.